

Final Committee Objectives 2020-21

State Legislative/Regulatory Committee

Chair: Danyelle Redden, MD, FACEP

Board Liaison: Alison J. Haddock, MD, FACEP

Staff Liaison: Harry Monroe

1. Monitor Medicaid payment reforms at the state level and provide resources as appropriate. Collaborate with the Reimbursement Committee to explore opportunities to advocate for alternative payment models for Medicaid. (State Legislative/Regulatory is the lead committee.)
2. Collaborate with the Reimbursement Committee to revise the Out-of-Network Consensus Principles and Proposed Solutions documents. (State Legislative/Regulatory is the lead committee.)
3. Research and summarize best practices by states working to overcome barriers to the provision of new treatments and modalities that reduce, when appropriate, the use of opioid medications.
4. Monitor legislative and regulatory efforts by nurse practitioners and physician assistants to expand their scope of practice in emergency medicine in a way that is inconsistent with ACEP policy and develop resources to assist state chapter advocacy on this issue.
5. Review the State Public Policy Grant Program criteria and process and make recommendations to improve the program.
6. Submit nominations for the 2021 Rorrie Health Policy Award and 2021 Policy Pioneer Award.
7. Monitor Medicaid reforms at the state level and provide resources as appropriate. Explore developing a model to implement the AUCM framework at the state level for Medicaid payors. Provide input to the Reimbursement Committee to coordinate with state chapter stakeholders in drafting the implementation process. (Reimbursement is the lead committee.)
8. Provide input to the Federal Government Affairs Committee in responding to federal legislative and regulatory action related to out-of-network billing. (Federal Government Affairs is the lead committee.)
9. Develop model state legislation for chapters to use to access funding related to the Preventing Overdoses While in the Emergency Rooms (POWER) Act and to address Amended Resolution 25(18) Funding for Medication Assisted Treatment Programs, Amended Resolution 26(18) Funding of Substance Use Intervention and Treatment Programs, and Amended Resolution 47(18) Supporting Medication for Opioid Use Disorder.
10. Complete development of an information paper and/or legislative toolkit to assist members in advocating for applicable changes to state insurance laws as directed in Amended Resolution 29(18) Insurance Collection of Patient Financial Responsibility.
11. Provide support to chapters to oppose legislation to add naloxone to state prescription drug monitoring programs and collaborate with chapters in developing strategies and supporting materials to stop such legislation, as directed in Amended Resolution 34(19) Opposing Naloxone Addition to the Prescription Drug Monitoring Program.
12. Provide input to the Federal Government Affairs Committee to develop strategies to address Amended Resolution 38(19) Standards for Insurance Denials. (Federal Government Affairs is the lead committee.)
13. Review state actions taken in response to the COVID-19 crisis. Prepare recommendations for legislative and regulatory actions that states can take to improve readiness for future national and regional crises. Give particular attention to matters related to physician licensure, telehealth, medical liability, and physician wellness.
14. Identify legislative and regulatory opportunities to address disparities in health care outcomes. Include consideration of social determinants of health that contribute to disparities across populations. Identify ACEP committees and sections that have created documentation on these issues and incorporate relevant work products in recommendations.